Pluristem Therapeutics Inc. announced that it has accomplished dosing of the first of three dosage groups of patients in Europe with its placenta-derived cell therapy product, PLX-PAD, in a Phase Me dose-escalating clinical trial for the treatment of critical limb ischemia the end-stage of peripheral artery disease.

The three patients treated in this group received the lowest of the three doses in the trial. The Data Safety Monitoring Board an independent board monitoring the safety of PLX-PAD will meet in about 30 days to determine dose escalation to the next dose level to be administered in this trial.

Last Trade: 1.13
Trade Time: Dec 24
Prev Close: 1.13
Open: N/A
Day’s Range: N/A – N/A
52wk Range: 0.38 – 2.29
Volume: 0
Avg Vol (3m): 102,595
Market Cap: 20.90M

About Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. is a bio-therapeutics company engaged in developing and intending to commercialize, cell therapy production technologies and products. The Company focuses on commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products, stored ready to use, that are derived from human placenta, a non-controversial, non-embryonic adult stromal cell source. The Company’s focuses in the development of product candidates for local administration for indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries. The Company focuses on developing Placenta expanded cells- peripheral artery disease (PLX-PAD) cells as an allogeneic therapeutic product to treat CLI which results from PAD.